about
Pharmacokinetic drug interactions in liver disease: An updateEffect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipientsTherapeutic drug monitoring in a developing nation: a clinical guide.Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism.Use of a physiologically based pharmacokinetic model for rats to study the influence of body fat mass and induction of CYP1A2 on the pharmacokinetics of TCDD.In vivo effects of Faizol Ubat Batuk, a herbal product on aminopyrine metabolism in rat hepatocytes.Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women.Melatonin therapy to improve nocturnal sleep in critically ill patients: encouraging results from a small randomised controlled trial.Use of drugs that act on the cytochrome P450 system in the elderly.Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model.Role of constitutive androstane receptor in Toll-like receptor-mediated regulation of gene expression of hepatic drug-metabolizing enzymes and transportersThe role of hepatic cytochrome P-450 in sepsis.The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update.Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.Psychophysiological stress: a significant parameter in drug pharmacokinetics.Pharmacogenetics of Ketamine-Induced Emergence Phenomena: A Pilot Study.Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.Pharmacokinetics and Differential Regulation of Cytochrome P450 Enzymes in Type 1 Allergic Mice.Study of the pharmacokinetic changes of Tramadol in diabetic rats.Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes.Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes.Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.Acetaminophen hepatotoxicity: the first 35 years.Effect of cyclophosphamide on serum cyclosporine levels at the conditioning of hematopoietic stem cell transplantation.Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function.Turpentine oil induced inflammation decreases absorption and increases distribution of phenacetin without altering its elimination process in rats.Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues.Lidocaine metabolism in isolated perfused liver from streptozotocin-induced diabetic rats.Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study.Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.Effects of Honokiol on CYP450 Activity and Transporter mRNA Expression in Type 2 Diabetic Rats.Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL).
P2860
Q26774479-E681922B-C7EB-42A8-96AE-172E24806BD6Q33849526-F865B96B-1497-4129-B2C8-572AF21E988FQ33908116-AC776769-5920-4E79-88A1-F6F78267AD4DQ33977228-D734917E-23D8-432B-A9B8-1281DD9F786CQ35039205-7D388F12-B5C1-4FC3-947B-BBE11CFD9AF6Q35258330-6B9478D3-78E4-4BF0-AEE2-2B6551D97F2EQ36233963-B0389351-3B0B-4251-BA51-60BEFA415D76Q36336055-E7009C8E-C986-4265-A6DC-EE390A1F1A33Q36749111-FBD7FDE0-D5CC-4D2C-BE7A-DB436D5D132CQ37222734-4FD7A1AF-72D8-4AED-8527-D780B1611BDFQ37393359-CEA6A39B-DEAF-4FD0-B060-5EA4BC89E18AQ37422667-6C1CBE47-ADA4-43EA-B31B-BDE944CB5C34Q37633942-BCADE333-C6C5-4E96-A4AB-09C9A88F84D8Q37770251-8A154A5D-324E-40E3-9510-59E1ADCD753DQ38016232-24B54446-7211-41E0-9C86-B76ED704E307Q38120048-F2E6D001-CC89-45F8-AF4A-505689B6A482Q38751555-56D744B7-1F8C-4879-931B-3691B030AD94Q38800092-A305BCA4-DAA8-4591-8347-9EF19DD6F13DQ38813488-58A75603-A204-4907-B9A3-8A09645AF96BQ39331057-DCF45768-8A43-4995-80A8-E56B75C7E779Q39367402-AAAF53EB-5D68-4A65-B311-4AAA27340069Q42140839-AD25F273-50F2-4592-9435-24EA2E7857E6Q42145594-C252484F-5EF8-4DA6-8A99-87ADB847C170Q43571907-79F57582-7CC0-4734-B240-DFAC293BD6BCQ43979608-A1C67609-AB13-4D03-BD9E-DD07EC72F4B2Q44661102-A4A7368F-6E80-4032-A77D-7C02ACAC7A4AQ46237124-7CF997AA-98EC-4C24-B735-F1CA1A16896EQ46809038-4D86DE79-BF3B-479F-886B-7868D6AA474EQ47911043-B13D234E-4C93-4602-AACD-609442756513Q48677642-22687826-2E06-47C1-955D-27B2FD0D6B65Q50035868-681EB6FD-0DF6-4488-95D9-9184C05E6665Q51739644-902A856C-AA7B-4532-A0E5-EA1D321211C6Q52657738-2E563885-EEE9-463D-A884-0A6E0AE14695Q55330048-F0D6BB12-38E7-4049-8F8A-7F81A2577490
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Hepatic cytochrome P450 regulation in disease states.
@ast
Hepatic cytochrome P450 regulation in disease states.
@en
Hepatic cytochrome P450 regulation in disease states.
@nl
type
label
Hepatic cytochrome P450 regulation in disease states.
@ast
Hepatic cytochrome P450 regulation in disease states.
@en
Hepatic cytochrome P450 regulation in disease states.
@nl
prefLabel
Hepatic cytochrome P450 regulation in disease states.
@ast
Hepatic cytochrome P450 regulation in disease states.
@en
Hepatic cytochrome P450 regulation in disease states.
@nl
P356
P1476
Hepatic cytochrome P450 regulation in disease states.
@en
P2093
P304
P356
10.2174/1389200013338676
P407
P577
2001-06-01T00:00:00Z